Senior Scientist, Inflammation & Chronic Disease
Ottawa Hospital Research Institute

Director, OHRI Centre for Transfusion Research, Clinical Epidemiology Program
Ottawa Hospital Research Institute

Head, Benign Hematology & Transfusion Medicine, Division of Hematology
Ottawa Hospital

My principal areas of research interest are;
-in the use of blood products, specifically frozen plasma and platelets, as hemostatic agents to achieve or maintain hemostasis,
-knowledge transfer research in transfusion medicine, specifically the use of interventions to change physician transfusion practice,
-the use of administrative and clinical databases as research tools to assess changes in transfusion practice. 
-collaboration with the BEST(Biomedical Excellence for Safer Transfusion) research group on monitoring the use of blood products by transfusion medicine research services.

Dr. Tinmouth received his M.D. from the University of Calgary in 1994 and a MSc (Clinical Epidemiology) from the University of Toronto in 2003. He completed his residency in Internal Medicine and Hematology at the University of Western Ontario (1994-1999). Subsequently he completed a fellowship in Transfusion Medicine at the Canadian Blood Services and the University Health Network in Toronto (1999-2001). Dr. Tinmouth’s research is supported by the Canadian Blood Services and the Canadian Institutes of Health Research.

Dr. Tinmouth is an Associate Professor in Medicine (Hematology) at the University of Ottawa and Associate Staff at the Ottawa Hospital since September 2002. Dr. Tinmouth is the Head of General Hematology and Transfusion Medicine. He is also a scientist at the Ottawa Hospital Research Institute and Director of the  Ottawa Hospital Research Institute's Centre for Transfusion Research. Dr. Tinmouth previously served as Associate Medical Director at the Canadian Blood Services Toronto Centre in 2001-2002 and continues to work as medical consultant to the Canadian Blood Services in Ottawa.

Tay J, Allan D, Beattie S, Bredeson C, Fergusson D, Maze D, Sabloff M, Thavorn K, Tinmouth A. Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study.
BMJ Open. 2016 Oct 24;6(10):e013483

Lacroix J, Hébert PC, Fergusson DA, Tinmouth A, Cook DJ, Marshall JC, Clayton L, McIntyre L, Callum J, Turgeon AF, Blajchman MA, Walsh TS, Stanworth SJ, Campbell H, Capellier G, Tiberghien P, Bardiaux L, van de Watering L, van der Meer NJ, Sabri E, Vo D; ABLE Investigators.; Canadian Critical Care Trials Group..Age of transfused blood in critically ill adults.   N Engl J Med. 2015 Apr 9;372(15):1410-8

Tinmouth A; Thompson T; Arnold DM; Callum JL; Gagliardi K; Lauzon D; Owens W; Pinkerton P, (2013 May 14), Utilization of frozen plasma in Ontario: a provincewide audit reveals a high rate of inappropriate transfusions, Transfusion, Vol.53, Issue 10, 2222-2229

Tinmouth A; MacDougall L; Fergusson D; Amin M; Graham ID; Hebert PC; Wilson K, (2005 Apr 25), Reducing the amount of blood transfused: a systematic review of behavioral interventions to change physicians' transfusion practices, Archives of Internal Medicine, Vol.165, Issue 8, 845-852

Tinmouth A; Tannock IF; Crump M; Tomlinson G; Brandwein J; Minden M; Sutton D, (2004 Dec), Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design.[see comment], Transfusion, Vol.44, Issue 12, 1711-1719

COVID-19; Sickle cell anemia; Thalassemia

Clinical trials; Epidemiology; Transfusions